Dignify Therapeutics Welcomes New Chief Operating Officer
Dignify Therapeutics, a pioneering company in the development of pharmaceutical and medical devices, is excited to announce the appointment of Jeff Welch as its Chief Operating Officer. As the organization focuses on enhancing bowel and bladder control treatments for elderly individuals and those with neurological impairments, Mr. Welch's extensive expertise will be invaluable.
Experience that Counts
With over two decades of diverse experience, Jeff Welch is not just an entrepreneur; he is a seasoned business executive who has successfully transitioned companies from startup phases to acquisitions. His career includes significant roles in clinical trials involving pharmaceutical, biotechnology, and medical technology companies. Mr. Welch has been instrumental in guiding these firms through the complex processes to create both safe and effective treatments.
A Vision for Growth
CEO Anthony DiTonno expressed enthusiasm about Jeff joining the team, stating, "We are thrilled to welcome Jeff to our executive team. His skills and experience align well with Dignify's business priorities, especially as we enter this pivotal growth phase. Jeff understands the intricate challenges that come with bringing a drug or device to market, from fundraising to understanding the regulatory environment. He will be crucial in helping us fulfill our mission of delivering innovative treatments to those in need."
About Dignify Therapeutics
Dignify Therapeutics was established by a highly recognized team of scientists and entrepreneurs with a mission to provide effective treatments for bladder and bowel voiding dysfunctions. The company focuses on a creative approach to drug discovery, known as repositioning, which has been successfully leveraged in fields such as urology and gastroenterology over the last 20 years.
Support and Funding
The company has garnered significant funding through various sources, including investment from venture capital firms, which include RA Capital Management and Eshelman Ventures, alongside support from the North Carolina Biotechnology Center and the One NC Small Business Program. The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have also contributed, with Dignify receiving 18 awards and close to $18 million in funding.
The Future of Bladder and Bowel Control Treatments
Dignify Therapeutics is located in the First Flight Venture Center, a collaborative space designed to foster innovation and growth. As the company continues to push the boundaries of medical science and technology, the addition of Jeff Welch to the executive team marks a significant step toward achieving its ambitious goals.
Frequently Asked Questions
Who is Jeff Welch?
Jeff Welch is the newly appointed Chief Operating Officer of Dignify Therapeutics and brings extensive experience in business development and clinical trials.
What is the mission of Dignify Therapeutics?
Dignify's mission is to create practical and innovative treatments for bladder and bowel control dysfunctions.
What funding sources support Dignify Therapeutics?
The company is supported by various venture capital firms, government programs, and private investments, totaling around $18 million.
Where is Dignify Therapeutics located?
Dignify Therapeutics is based in the First Flight Venture Center, a hub for innovation.
What challenges does Dignify face in its mission?
The company navigates complexities in regulatory approvals and market entry strategies while aiming to deliver effective treatments to patients.
